On November 12, 2025, Michigan joined the growing list of states that have introduced legislation prohibiting the sale of over-the-counter products and dietary supplements for weight loss or muscle building to consumers under the age of 18. House Bill No. 5250 (HB 5250) was formally introduced in the Michigan House of Representatives on Wednesday and referred to the House Health Policy Committee.
The proposed legislation would prohibit selling “dietary supplements for weight loss or muscle building” or “over-the-counter diet pills” to anyone under 18. The proposed legislation would also require retailers to require proof of legal age prior to purchase. For online purchases, consumers would need to provide their full name, date of birth, and residential address, and the retailer would then need to use a commercial database to verify the consumer’s identity. Additionally, the delivery method that the retailer uses would need to require the person accepting delivery to provide identification proving they are of legal age.
HB 5250 defines “dietary supplements for weight loss or muscle building” as a dietary supplement “that is labeled, marketed, or represented for the purpose of achieving weight loss, fat burning, appetite control, or muscle building, or that contains an ingredient that is regulated by [FDA] for weight loss.” The bill defines “over-the-counter diet pills” as “a class of drugs labeled, marketed, or otherwise represented for the purpose of achieving weight loss, that are lawfully sold, transferred, or furnished over-the-counter with or without a prescription.” The bill lists many factors that the Michigan Department of Licensing and Regulatory Affairs would consider in determining whether a product meets those definitions, including whether it contains creatine, green tea extract, raspberry ketone, Garcinia cambogia, or coffee bean extract.
If the bill is passed, retailers will be subject to civil fines of up to $1,000 per violation. Trade associations like the Counsel for Responsible Nutrition are currently holding discussions with stakeholders in Michigan regarding the proposed act. A similar bill was introduced in Michigan in 2024 (HB 5830) but did not advance.
While this bill is pending, it is important to consider how it may affect the sale of your products. Venable’s FDA and legislative teams are closely monitoring this bill, along with other pertinent legislation, and will continue to report on any crucial developments.
*The authors would like to thank Destiny Brown, a law clerk in the Washington, D.C. office, for her assistance with this publication.